In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Esperance raises $5.7mm through first closing of Series B round

Executive Summary

Esperance Pharmaceuticals Inc. (anticancer peptide therapeutics) raised $5.7mm in the first closing of its Series B round, which is expected to generate a total of $7.5mm. Sanofi invested $4.5mm, and earmarked $1.5mm of that specifically for clinical and regulatory services related to continued development of Esperance's EP100, a Phase I solid tumor candidate. All of Esperance's existing backers also participated including Louisiana Fund I, Themelios Ventures (managed by BVM Capital), Research Corp. Technologies, Advantage Capital Partners/Louisiana Technology Fund, and five other investors.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register